Green Cross
107, Ihyeon-ro 30beon-gil, Yongin-si, Gyeonggi-do, 446-770, South Korea
Overview
Green Cross continues to build on a long legacy of providing life-saving and life-sustaining specialty therapeutics. Their bioscience division began its business in 1971 as producing plasma-derived biotherapies for the first time in Korea. For more than 40 years, they have specialized in providing biotherapeutics to improve the quality of life for people with rare and serious diseases worldwide. Their vaccine business develops and produces paediatric and adult vaccine against a broad range of infectious diseases, from world’s 3rd hepatitis B vaccine to quadrivalent influenza vaccine. With their mission to improve health and well-being of people around the world, they have gone down a path that nobody wishes to explore. Their extensive research and development of innovative medicines that support treatment and prevention as well as cures for diseases in a wide range of therapeutic areas demonstrate their ongoing commitment to all people who rely on their products.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 1
Sector focus
- Biotechnology
- Health Care
- Sustainability
Investment portfolio
- Genoplan
Participated · Series B · Apr 2017
Genoplan positions itself around cutting-edge medical technology and scientific innovation, stating its mission to help reshape customers' futures. The company maintains a homepage at www.genoplan.com. According to the listing, Genoplan completed a $15M Series B in November 2018. Participating investors listed include Softbank Ventures Asia, Samsung Ventures, Green Cross, Dayli Partners, and PIA Investment Management. The article presents Genoplan as a portfolio company of SparkLabs Korea. The article provides no operating metrics, product details, or further financial information beyond the Series B.
Team
Mikhail Gorbachev
Founder